亚洲呦女专区,国内2020揄拍人妻在线视频

首頁> 產(chǎn)品列表> 納米碳材料納米碳單元結(jié)構(gòu)材料>

Lefradafiban

NMR下載 COA and HPLC MSDS下載
names：
methyl 2-((3S,5S)-5-(((4'-(N-(methoxycarbonyl)carbamimidoyl)-[1,1'-biphenyl]-4-yl)oxy)methyl)-2-oxopyrrolidin-3-yl)acetate
CAS號(hào)：
149503-79-7
MDL Number：
MF(分子式)： C23H25N3O6 MW(分子量)： 439.468
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

貨品編碼	規(guī)格	純度	價(jià)格 (￥)	現(xiàn)價(jià)(￥)	特價(jià)(￥)	庫(kù)存描述	數(shù)量	總計(jì) (￥)

大包裝詢價(jià) 提供各種包裝，敬請(qǐng)垂詢
收藏商品商品點(diǎn)評(píng) 加入購(gòu)物車立即購(gòu)買

快速詢價(jià)

收起

你想詢價(jià)的產(chǎn)品

*產(chǎn)品名稱：

CAS號(hào)：

產(chǎn)品編號(hào)：

需求描述：

請(qǐng)準(zhǔn)確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗(yàn)證碼：

詢價(jià)

中文別名	Lefradafiban
英文別名	Lefradafiban; BIBU-104; BIBU 104; BIBU104.
CAS號(hào)	149503-79-7
Inchi	InChI=1S/C23H25N3O6/c1-30-20(27)12-17-11-18(25-22(17)28)13-32-19-9-7-15(8-10-19)14-3-5-16(6-4-14)21(24)26-23(29)31-2/h3-10,17-18H,11-13H2,1-2H3,(H,25,28)(H2,24,26,29)/t17-,18-/m0/s1
InchiKey	PGCFXITVMNNKON-ROUUACIJSA-N
分子式 Formula	C23H25N3O6
分子量 Molecular Weight	439.468
溶解度Solubility
性狀	Solid powder
儲(chǔ)藏條件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

產(chǎn)品說明	Lefradafiban(CAS:149503-79-7):僅限應(yīng)用于工業(yè)或者科學(xué)研究過程中非醫(yī)療目的，不應(yīng)用于人類或動(dòng)物的臨床診斷以及治過程療，該產(chǎn)品非藥用，非食用。
Introduction	Lefradafiban, also known as BIBU-104, is a glycoprotein IIb/IIIa receptor antagonist potentially for the treatment of thrombosis.
Application1
Application2
Application3

警示圖
危險(xiǎn)性	Warning
危險(xiǎn)性警示
安全聲明
安全防護(hù)
備注

[1]Kostewicz ES, Wunderlich M, Brauns U, Becker R, Bock T, Dressman JB. Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol. 2004 Jan;56(1):43-5[1]PubMed PMID: 14980000.

[2]Doggrell SA. Clinical trials with glycoprotein IIb/IIIa antagonists - No benefit without bleeding? Drugs Today (Barc). 2001 Aug;37(8):509-531. PubMed PMID: 12743636.

[3] Nicholson NS, Abood NA, Panzer-Knodle SG, Frederick LG, Page JD, Salyers AK, Suleymanov OD, Szalony JA, Taite BB, Anders RJ. Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev. 2001 May;21(3):211-26. PubMed PMID: 11301411.

[4] Akkerhuis KM, van Den Brand MJ, van Der Zwaan C, Peels HO, Suryapranata H, van Der Wieken LR, Stibbe J, Hoffmann J, Baardman T, Deckers JW, Simoons ML. Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50. PubMed PMID: 11250974; PubMed Central PMCID: PMC1729676.

[5] McDonagh MS, Bachmann LM, Golder S, Kleijnen J, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina. Health Technol Assess. 2000;4(30):1-95. Review. PubMed PMID: 11154975.

6: Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML; Fibrinogen Receptor Occupancy Study (FROST) Investigators. Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study. Eur Heart J. 2000 Dec;21(24):2042-55. PubMed PMID: 11102255.7: Curtin R, Fitzgerald DJ. A cold start for oral glycoprotein IIb/IIIa antagonists. Eur Heart J. 2000 Dec;21(24):1992-4. PubMed PMID: 11102247.8: Drewe J, Narjes H, Heinzel G, Brickl RS, Rohr A, Beglinger C. Absorption of lefradafiban from different sites of the gastrointestinal tract. Br J Clin Pharmacol. 2000 Jul;50(1):69-72. PubMed PMID: 10886122; PubMed Central PMCID: PMC2014969.9: Lefradafiban. BIBU 104, BIBU 104XX. Drugs R D. 1999 May;1(5):383-4. PubMed PMID: 10566070.10: Storey RF, May JA, Wilcox RG, Heptinstall S. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies. Thromb Haemost. 1999 Oct;82(4):1307-11. PubMed PMID: 10544919.1

對(duì)不起，暫無產(chǎn)品評(píng)價(jià)！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開